Christine Geffriaud-Ricouard

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

Ronald de Wit, Johann S. de Bono, Cora N. Sternberg et al. · New England Journal of Medicine · 2019 · 634 citations · Full text

Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic Hyperplasia

F.M.J. Debruyne, A Jardin, D. Colloi et al. · European Urology · 1998 · 227 citations

Urology, Sustained-release Alfuzosin, Medicine +3

Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients.

Christine Geffriaud-Ricouard, L.H. Noël, Dominique Chauveau et al. · PubMed · 1993 · 147 citations

Efficacy and Safety of Sustained-Release Alfuzosin 5 mg in Patientswith Benign Prostatic Hyperplasia

J M Buzelin, S H Roth, Christine Geffriaud-Ricouard et al. · European Urology · 1997 · 82 citations

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

Karim Fizazi, Gero Kramer, Jean-Christophe Eymard et al. · The Lancet Oncology · 2020 · 65 citations · Full text

Quality Of Life, Metastatic Prostate Cancer, Urology +8